Recombinant Human Endostatin Market Drivers
Government initiatives to reduce prices of anticancer drugs is expected to drive growth of the recombinant human endostatin market during the forecast period. For instance, in August 2018, Government of China took initiatives to reduce prices of anticancer drugs by 44%. Chinese National Health and Family Planning Commission organized a national-wide drug price and reimbursement drug list negotiation, in which a total of 39 products have been successfully added including recombinant human endostatin.
Increasing research and development activities for identifying potential uses of recombinant human endostatin is expected to propel growth of the market. For instance, according to a paper published in the journal Nature, September 2015, a study was conducted to evaluate effects of recombinant human endostatin in combination with radiotherapy for treating esophageal squamous cell carcinoma and to discover its potential mechanisms. These findings suggested that recombinant human endostatin is a potential anti-angiogenic agent in esophageal squamous cell carcinoma mainly when combined with radiotherapy.
Furthermore, according to National Center for Biotechnology Information (NCBI) January 2017, recombinant human endostatin in combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) may aid in treatment of Angioimmunoblastic T Cell Lymphoma (AITL), a form of Peripheral T Cell Lymphoma (PTCL). Such novel therapies for PTCL treatment are immediately desired to improve the outcomes of patients with this disease. These factors are expected to propel growth of the recombinant human endostatin market.
Recombinant Human Endostatin Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients